Colossal Biosciences reportedly in talks to raise new capital at $20B–$30B valuation
THE SO WHAT
A de-extinction startup chasing a $20B–$30B valuation shows how much capital is willing to price in long-dated, high-science optionality. Deep tech founders can expect more appetite for bold narratives—but should assume diligence will center on IP defensibility and regulatory path, not just story.
READ THE SOURCE
MORE FROM THE WIRE
Startups & VentureUniversity of Bristol spinouts looking to raise
University spinouts shopping for capital are a reminder that frontier IP is still leaking out of academia before it’s fully de-risked. If you’re an operator nearby, treat these teams as option value on future tech partnerships rather than just another funding headline.
Startups & VentureSingapore-based Ant International, a payments company which spun out of Ant Group in 2024, raised $1.2B from investors including Ant Group and Alibaba
$1.2B into Ant International’s overseas push is a reminder that cross-border payments and merchant services are still in land-grab mode. If you rely on payments as a margin pool or data moat, assume more price pressure and tighter integration between wallets, checkout, and credit in Asia-linked corridors.
Startups & VentureSBI Funds Poised for Strong India Debut After $1 Billion IPO
Oversubscribed $1 billion asset-management IPOs in India point to deepening local capital pools for financial infrastructure. If you're building in or selling into India, assume more sophisticated domestic LP/allocator behavior and faster follow-on capital for scaled managers.
Startups & VentureChina’s GigaAI Seeks 2026 Hong Kong IPO in First for World Model
Chinese foundation model vendors heading for Hong Kong listings means public markets are now underwriting national AI capacity, not just private capital. If you operate in or with China, assume model access, pricing, and regulatory posture will be shaped by listed-company disclosure and state-aligned expectations.